Ling LE, Hillson JL, Tiessen RG, et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105(4):1031–9.

Article  PubMed  CAS  Google Scholar 

Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427–38.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moise KJ Jr, Ling LE, Oepkes D, et al. Nipocalimab in early-onset severe hemolytic disease of the fetus and newborn. N Engl J Med. 2024;391(6):526–37.

Article  PubMed  CAS  Google Scholar 

Gottenberg J, Sivils K, Campbell K, et al. Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary sjogren’s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS) [abstract no. LBA0010]. Ann Rheum Dis. 2024;83(Suppl 1):240.

Article  Google Scholar 

Taylor PC, Schett G, Huizinga TW, et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024;10(e004278):1–12.

Google Scholar 

Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105–16.

Article  PubMed  CAS  Google Scholar 

Janssen Pharmaceutical Companies. IMAAVYTM (nipocalimab-aahu) injection, for intravenous use; US prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761430s000lbl.pdf. Accessed 23 May 2025.

Johnson & Johnson. Johnson Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) [media release]. https://www.multivu.com/johnson-johnson/9331651-en-johnson-johnson-receives-fda-approval-imaavy-nipocalimab-aahu. Accessed 30 Apr 2025.

Janssen. J&J files nipocalimab for generalized myasthenia gravis in Japan [media release]. https://pj.jiho.jp/article/252421. Accessed 31 Jan 2025.

Janssen. Johnson Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis [media release]. https://www.investor.jnj.com/. Accessed 12 Sept 2024.

Momenta Pharmaceuticals. Momenta pharmaceuticals announces expiration of Hart-Scott-Rodino waiting period in connection with proposed sale to Johnson & Johnson [media release]. http://www.momentapharma.com. Accessed 15 Sept 2020.

Sivils K, Leonardo S, Li H, et al. Pharmacodynamic effects of nipocalimab on disease biomarkers in patients with moderate-to-severe active Sjogren’s disease: results from a multicenter, randomized, double-blinded, placebo-controlled phase 2 study [abstract no. 2294]. Arthritis Rheumatol. 2024;76(Suppl 9):4616–8.

Google Scholar 

Matsushima N, Shibata S, Leu JH, et al. Pharmacokinetics and pharmacodynamics of nipocalimab, a neonatal Fc receptor blocker, in healthy Japanese volunteers. Clin Drug Investig. 2024;44(8):587–99.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Antozzi C, Guptill J, Bril V, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study. Neurology. 2024;102:1–14.

Article  Google Scholar 

Strober J, Black S, Ramchandren S, et al. Safety and effectiveness of nipocalimab in adolescent participants in the open label phase 2/3 VIBRANCE-MG clinical study [abstract no. MG66]. Muscle Nerve. 2024;70(3):676.

Google Scholar 

Komatsu Y, Verweij E, Tiblad E, et al. Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn. Am J Perinatol. 2025;42(7):842–53.

Article  PubMed  Google Scholar 

Bussel JB, Baker P, Lam E, et al. Design of a phase 3, multicenter, randomized, open-label study of nipocalimab or ivig in pregnancies at risk for fetal and neonatal alloimmune thrombocytopenia (FREESIA-3) [abstract no. 1193.1 plus poster]. Blood. 2024;144(Suppl 1):1193.1.

Article  Google Scholar 

Vaikunthanathan T, Murakhovskaya I, Fattizzo B, et al. Designing ENERGY: a phase 2/3 study of nipocalimab in warm autoimmune haemolytic anaemia [abstract no. BSH23-PO112]. Br J Haematol. 2023;201(Suppl 1):43.

Google Scholar 

Ford L, Wong J, Youssef E, et al. A phase 2/3 placebo-controlled, parallel group, randomized withdrawal study to evaluate the efficacy and safety of nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy: the ARISE study [abstract no. P14-8.006]. Neurology. 2023;100(17 Suppl 2):8.006.

Google Scholar 

Najem C, Craig J, Christopher Stine L, et al. A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA): study design [abstract no. AB0250]. Ann Rheum Dis. 2024;83(Suppl 1):1365.

Article  Google Scholar 

Liu-Walsh F, Hartingsveldt BV, Zuraw Q, et al. Efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus: design of a phase 2 study [abstract no. AB0548]. Ann Rheum Dis. 2023;82(Suppl 1):1472–3.

Article  Google Scholar